Cormorant Asset Management, LP
Cormorant Asset Management, LP reported 50 holdings worth US$1.95B as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 14, 2026
Cormorant Asset Management, LP reported 50 holdings worth US$1.95B as of Jun 30, 2026. Largest: Praxis Precision Medicines, Inc., Bridgebio Oncology Therapeutics, Inc. and Parabilis Medicines, Inc. Filed Aug 14, 2026 (Form 13F).
- Holdings
- 50
- Value as reported
- US$1.95B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Praxis Precision Medicines, Inc. | 640K | US$214M | 11.0% |
| Bridgebio Oncology Therapeutics, Inc. | 17.9M | US$136M | 7.0% |
| Parabilis Medicines, Inc. | 4.62M | US$126M | 6.5% |
| Rapport Therapeutics, Inc. | 2.66M | US$111M | 5.7% |
| Erasca, Inc. | 6M | US$110M | 5.6% |
| Edgewise Therapeutics, Inc. | 2.51M | US$102M | 5.2% |
| Eyepoint, Inc. | 7M | US$100M | 5.1% |
| Alumis Inc. | 3.29M | US$92.5M | 4.7% |
| Abivax Sa | 675K | US$90M | 4.6% |
| Dianthus Therapeutics, Inc. | 750K | US$73.1M | 3.7% |
| Bright Minds Biosciences Inc. | 900K | US$63.2M | 3.2% |
| Bioage Labs, Inc. | 2.39M | US$58.6M | 3.0% |
| Oruka Therapeutics, Inc. | 533K | US$50.8M | 2.6% |
| Bridgebio Pharma, Inc. | 550K | US$41M | 2.1% |
| Tango Therapeutics, Inc. | 1.3M | US$40.6M | 2.1% |
| Biohaven Ltd. | 2.61M | US$38.8M | 2.0% |
| Mbx Biosciences, Inc. | 550K | US$30.4M | 1.6% |
| Climb Bio, Inc. | 2.11M | US$27.5M | 1.4% |
| Olema Pharmaceuticals, Inc. | 2.15M | US$26.9M | 1.4% |
| Damora Therapeutics, Inc. | 1M | US$26M | 1.3% |
| Corbus Pharmaceuticals Holdings, Inc. | 2.34M | US$22M | 1.1% |
| Spyre Therapeutics, Inc. | 225K | US$20M | 1.0% |
| Definium Therapeutics, Inc. | 400K | US$18.8M | 0.96% |
| Roivant Sciences Ltd. | 475K | US$16.8M | 0.86% |
| Cabaletta Bio, Inc. | 5M | US$15.6M | 0.80% |
| Helix Acquisition Corp. Iii | 1.3M | US$13.8M | 0.71% |
| Kailera Therapeutics, Inc. | 550K | US$12.1M | 0.62% |
| Insmed Incorporated | 75,000 | US$8M | 0.41% |
| Sensei Biotherapeutics, Inc. | 1.03M | US$7.66M | 0.39% |
| Enliven Therapeutics, Inc. | 150K | US$7.61M | 0.39% |
| Tarsus Pharmaceuticals, Inc. | 100K | US$6.29M | 0.32% |
| Ibio, Inc. | 3.57M | US$6.25M | 0.32% |
| Crinetics Pharmaceuticals, Inc. | 125K | US$4.68M | 0.24% |
| Arcutis Biotherapeutics, Inc. | 175K | US$4.59M | 0.24% |
| Arrowhead Pharmaceuticals, Inc. | 50,000 | US$4.08M | 0.21% |
| Research Alliance Corporation Iii | 370K | US$3.96M | 0.20% |
| Cogent Biosciences, Inc. | 100K | US$3.87M | 0.20% |
| Altimmune, Inc. | 1.25M | US$3.8M | 0.19% |
| Amylyx Pharmaceuticals, Inc. | 200K | US$3.59M | 0.18% |
| Odyssey Therapeutics, Inc. | 175K | US$3.27M | 0.17% |
| Vaxcyte, Inc. | 50,000 | US$2.91M | 0.15% |
| Boundless Bio, Inc. | 1M | US$2.5M | 0.13% |
| Zura Bio Limited | 0 | US$0 | 0.00% |
| Ascendis Pharma A/s | 0 | US$0 | 0.00% |
| Axsome Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Context Therapeutics Inc. | 0 | US$0 | 0.00% |
| Maze Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Monte Rosa Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Rallybio Corporation | 0 | US$0 | 0.00% |
| Terns Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
Source
View original at SEC
Related